HGH Fragment 176-191-Jiangxi ShengtianTuYuan Biotechnology Co., Ltd.

About Us

We are an enterprise integrating chemical research and development, production and trading, specializing in the operation of high-quality fine chemical products.

Company adopts an advanced management model, possesses a professional R&D team, strong technical strength, a complete quality assurance and control system, excellent sales and after-sales service, forming a complete system from product R&D, production, sales to after-sales service, ensuring the highest quality and timely delivery.

We are extremely committed to the collection and research and development of both new and old products. Adhering to the business philosophy of "sincerity and trustworthiness, customer satisfaction first", we follow the path of professional development and have won high praise and a good reputation from customers with excellent product quality and perfect and considerate services. To become a leading import and export enterprise of pharmaceuticals and chemicals in China. Processing capacity: The company has strong technical force and advanced testing equipment, and can provide high-quality products ranging from gram level to kilogram level and ton level. After-sales service: Made in China, reasonable price, superior quality. 24-hour online service. 3. Safe and fast global delivery. 4. High-quality after-sales service with customer satisfaction as the goal.

Description
Additional information

Basic Info.

The synthetic peptides corresponding to amino acids 172-191, 176-191, 177-191, 178-191, 179-191, and 180-191 of human growth hormone (HGH) have been studied for their in vivo effects in normal rats.

Four of the peptides produced a short-lived rise in blood glucose and a more sustained rise in plasma insulin, whereas the other two (HGH 179-191 and 180-191) were inert in the systems tested. A single dose of the peptides containing the amino acids sequence 178-191 of the hGH molecule significantly reduced insulin sensitivity of the animals in intravenous insulin tolerance tests.

The findings also indicate that the biologically active peptides must not only have the minimum of the informational sequence but also that this must be in correct physical configuration.